Gerben Bouma

Gerben Bouma

Auto-generated profile, based on publicly available information

Gerben Bouma

Translational Science and Experimental Medicine, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
Luis ApoloniaLuis Apolonia
Luis Apolonia
SWSimon Waddington
Simon Waddington
CFCarolina Fernandes
Carolina Fernandes
NWNatalie J Ward
Natalie J Ward
GBGerben Bouma
Gerben Bouma
NPNicola J Philpott
Nicola J Philpott
Human immunodeficiency virus (HIV)-based lentiviral vectors (LVs) hold immense promise for gene delivery applications because of their relatively large packaging capacity and their ability to infect a range of cell types. The genome of HIV non-specifically integrates into the host genome, and this promotes efficient, stable transgene expression in dividing cells. However, integration can also be problematic because of variations in gene expression among cells, possible gene silencing and, most importantly, insertional mutagenesis which can lead to undesirable effects such as malignant transformation. In order to alleviate these problems, we have developed a range of non-integrating LVs (NILVs) by introducing point mutations into the catalytic site, chromosome binding site, and viral DNA binding site of the viral integrase (IN). In addition, we have mutated the IN attachment (att) sites within the HIV long terminal repeats (LTRs). All of the vectors produced show efficient reverse transcription and transgene expression in dividing cells and prolonged expression in non-dividing myotubes. Finally, we show that NILV can be used for achieving highly effective gene transfer and expression in muscle in vivo.

1 September 2009 in Immunobiology
Verified
Journal Article
Open access
GBGerben Bouma
Gerben Bouma
SBSiobhan O. Burns
Siobhan O. Burns
ATAdrian J. Thrasher
Adrian J. Thrasher
Regulation of the actin cytoskeleton is crucial for many aspects of correct and cooperative functioning of immune cells, such as migration, antigen uptake and cell activation. The Wiskott-Aldrich Syndrome protein (WASp) is an important regulator of actin cytoskeletal rearrangements and lack of this protein results in impaired immune function. This review discusses recent new insights of the role of WASp at molecular and cellular level and evaluates how WASp deficiency affects important immunological features and how defective immune cell function contributes to compromised host defence.

15 September 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MBMichael P. Blundell
Michael P. Blundell
GBGerben Bouma
Gerben Bouma
JMJoao Metelo
Joao Metelo
AWAusten Worth
Austen Worth
YCYolanda Calle
Yolanda Calle
ATAdrian J. Thrasher
Adrian J. Thrasher
The Wiskott-Aldrich syndrome protein (WASp) is a key cytoskeletal regulator in hematopoietic cells. Covalent modification of a conserved tyrosine by phosphorylation has emerged as an important potential determinant of activity, although the physiological significance remains uncertain. In a murine knockin model, mutation resulting in inability to phosphorylate Y293 (Y293F) mimicked many features of complete WASp-deficiency. Although a phosphomimicking mutant Y293E conferred enhanced actin-polymerization, the cellular phenotype was similar due to functional dysregulation. Furthermore, steady-state levels of Y293E-WASp were markedly reduced compared to wild-type WASp and Y293F-WASp, although partially recoverable by treatment of cells with proteasome inhibitors. Consequently, tyrosine phosphorylation plays a critical role in normal activation of WASp in vivo, and is indispensible for multiple tasks including proliferation, phagocytosis, chemotaxis, and assembly of adhesion structures. Furthermore, it may target WASp for proteasome-mediated degradation, thereby providing a default mechanism for self-limiting stimulation of the Arp2/3 complex.

1 August 2004 in Diabetes
Verified
Journal Article
Closed access
PDF file
GBGerben Bouma
Gerben Bouma
WLWai Kwan Lam-Tse
Wai Kwan Lam-Tse
AWAnnet F. Wierenga-Wolf
Annet F. Wierenga-Wolf
HDHemmo A. Drexhage
Hemmo A. Drexhage
MVMarjan A. Versnel
Marjan A. Versnel
The recruitment of monocytes from the bloodstream is crucial in the accumulation of macrophages and dendritic cells in type 1 diabetic pancreases. Adhesion via integrins to endothelium and extracellular matrix proteins, such as fibronectin (FN), and the production of myeloid-related protein (MRP)-8, -14, and -8/14 by recently transmigrated monocytes are thought to be instrumental in such recruitment. We determined the FN-adhesive capacity and integrin expression of monocytes of type 1 and type 2 diabetic patients and related them to the subjects’ serum levels of MRP-8, -14 and -8/14. Monocytes of type 1 diabetic patients displayed an increased adhesion to fibronectin in comparison with type 2 patients and healthy control subjects but had a normal expression of the FN binding integrins CD29, CD49a, CD49d, and CD49e (although CD11b and CD18 expression was increased). MRP-8/14, which was increased in the sera of type 1 diabetic patients, induced healthy donor monocytes to adhere to FN and upregulate CD11b expression in a dosage-dependent manner. The observed MRP-induced increased adhesion of monocytes to FN and upregulation of CD11b most likely contributed to a facilitated accumulation of monocytes and monocyte-derived cells at the site of inflammation, in this case the pancreatic islets.

22 March 2012 in Blood
Verified
Journal Article
Open access
PDF file
MRMike Recher
Mike Recher
SBSiobhan O. Burns
Siobhan O. Burns
MFMiguel Angel de la fuente
Miguel Angel de la fuente
SVstefano volpi
stefano volpi
CDCarin Dahlberg
Carin Dahlberg
LNLuigi Daniele Notarangelo
Luigi Daniele Notarangelo
Wiskott Aldrich syndrome (WAS) is caused by mutations in the WAS gene that encodes for a protein (WASp) involved in cytoskeleton organization in hematopoietic cells. Several distinctive abnormalities of T, B, and natural killer lymphocytes; dendritic cells; and phagocytes have been found in WASp-deficient patients and mice; however, the in vivo consequence of WASp deficiency within individual blood cell lineages has not been definitively evaluated. By conditional gene deletion we have generated mice with selective deficiency of WASp in the B-cell lineage (B/WcKO mice). We show that this is sufficient to cause a severe reduction of marginal zone B cells and inability to respond to type II T-independent Ags, thereby recapitulating phenotypic features of complete WASp deficiency. In addition, B/WcKO mice showed prominent signs of B-cell dysregulation, as indicated by an increase in serum IgM levels, expansion of germinal center B cells and plasma cells, and elevated autoantibody production. These findings are accompanied by hyperproliferation of WASp-deficient follicular and germinal center B cells in heterozygous B/WcKO mice in vivo and excessive differentiation of WASp-deficient B cells into class-switched plasmablasts in vitro, suggesting that WASp-dependent B cell–intrinsic mechanisms critically contribute to WAS-associated autoimmunity.

24 September 2015 in Blood
Verified
Journal Article
Closed access
PDF file
JRJulien Record
Julien Record
DMDessislava Malinova
Dessislava Malinova
HZHelen L. Zenner
Helen L. Zenner
VPVincent Plagnol
Vincent Plagnol
KNKarolin Nowak
Karolin Nowak
SBSiobhan O. Burns
Siobhan O. Burns
Megakaryoblastic leukemia 1 (MKL1), also known as MAL or myocardin-related transcription factor A (MRTF-A), is a coactivator of serum response factor, which regulates transcription of actin and actin cytoskeleton–related genes. MKL1 is known to be important for megakaryocyte differentiation and function in mice, but its role in immune cells is unexplored. Here we report a patient with a homozygous nonsense mutation in the MKL1 gene resulting in immunodeficiency characterized predominantly by susceptibility to severe bacterial infection. We show that loss of MKL1 protein expression causes a dramatic loss of filamentous actin (F-actin) content in lymphoid and myeloid lineage immune cells and widespread cytoskeletal dysfunction. MKL1-deficient neutrophils displayed reduced phagocytosis and almost complete abrogation of migration in vitro. Similarly, primary dendritic cells were unable to spread normally or to form podosomes. Silencing of MKL1 in myeloid cell lines revealed that F-actin assembly was abrogated through reduction of globular actin (G-actin) levels and disturbed expression of multiple actin-regulating genes. Impaired migration of these cells was associated with failure of uropod retraction likely due to altered contractility and adhesion, evidenced by reduced expression of the myosin light chain 9 (MYL9) component of myosin II complex and overexpression of CD11b integrin. Together, our results show that MKL1 is a nonredundant regulator of cytoskeleton-associated functions in immune cells and fibroblasts and that its depletion underlies a novel human primary immunodeficiency. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points MKL1 deficiency results in actin cytoskeletal disruption in myeloid and lymphoid cell lineages. MKL1 deficiency impairs neutrophil migration associated with downregulation of myosin II.